February 01, 2008 Dr. Bin Zhang, PhD awarded prestigious Basil O'Connor Starter Scholar Research Award from March of Dimes The March of Dimes Foundation has awarded Bin Zhang, PhD, Assistant Staff, GMI, a Basil O'Connor Starter Scholar Award for his proposed work entitled,» Receptor - Mediated ER - to - Golgi Transport of
Coagulation Factors V and VIII: Deficiencies in the Early Secretory Pathway as Pathogenic Mechanisms of Congenital Disorders.»
Not exact matches
The researchers found that patients both experiencing a reactional episode and those with non-reactional leprosy
had factors in their blood — including plasmatic fibrinogen, anti-cardiolipin antibodies, von Willebrand
factor, and soluble tissue
factor — promoting blood
coagulation.
An international team of scientists
have published a study in The Journal of Clinical Investigation, where they show that the disease is caused by a defective blood protein, the so - called
coagulation factor XII.
The strategy of giving a higher proportion of plasma is based on the belief that maintaining the balance of
coagulation factors carried in plasma
would reduce the overall amount of bleeding, requiring lower amounts of red blood cells and improving survival.
The increased production of PAI - 1 and
factor VII
has been implicated in the development of
coagulation and fibrinolytic abnormalities characteristic of obesity (28, 70).
Factor VIIIa is also inactivated by a protein in the
coagulation cascade called activated protein C. Gale and his colleagues hope that activated protein C
would still be able to degrade
Factor VIIIa and that clotting
would not get out of hand.
Inclusion Criteria: Subjects must
have histologically or cytologically confirmed metastatic cutaneous or mucosal melanoma, Able to swallow and retain orally administered medication, Adequate hematological, renal, hepatic, and
coagulation laboratory assessments Exclusion Criteria: Clinically significant bleeding within 4 weeks of screening, Current use of warfarin,
factor Xa inhibitors, and direct thrombin inhibitors, Infection requiring anti-infective treatments within 1 week of study enrollment, Anti-tumor therapy, Major surgery within 28 days
The condition is a result of a deficiency or dysfunction in a
coagulation factor known as Factor IX and it currently has no
factor known as
Factor IX and it currently has no
Factor IX and it currently
has no cure.
When injured, hemophiliacs tend to
have a slow clotting (
coagulation) process because of the lack of necessary blood
factors (proteins).
In collaboration with an international team, researchers at Karolinska Institutet in Sweden
have developed an antibody, 3F7, which blocks a protein that is active in the
coagulation system
factor XII.
Coagulation genetic markers, such as
Factor V Leiden and Prothrombin G20210A Mutation, determine whether a patient is at significantly higher risk for blood clotting.
Dogs affected with VWDI
have less than half of the normal level of von Willebrand
coagulation factor (vWf), which is an essential protein needed for normal blood clotting.